COVID-19

← Back to Index (Infectious Diseases)

Introduction And Epidemiology

Coronavirus disease 2019 is a diverse clinical syndrome caused by the severe acute respiratory syndrome coronavirus 2.
Surveillance data indicates children constituted approximately 18% of all reported cases globally between 2020 and 2023.
The epidemiological landscape features a distinct age-stratified risk profile, characterized by the healthy infant paradox.
While adolescents typically experience mild acute disease, otherwise healthy infants under two years of age remain disproportionately vulnerable, accounting for 54% of pediatric disease-related deaths and 57% of hospitalizations.
This heightened infant vulnerability results directly from anatomical airway differences and profound immunological immaturity.
Viral evolution altered clinical pathogenicity; the Delta variant triggered increased hospitalization rates, whereas the Omicron variant caused less severe individual disease but drove massive pediatric hospitalization volumes due to unprecedented transmissibility.

Pathophysiology

Viral Entry And Cellular Tropism

The virus utilizes its structural spike protein to bind the host Angiotensin-Converting Enzyme 2 receptor.
Viral entry requires priming by the host protease TMPRSS2, facilitating direct membrane fusion.
Receptors are abundantly expressed across the nasal epithelium, alveolar epithelial cells, enterocytes of the ileum and colon, myocardium, kidneys, and vascular endothelium.
The Omicron variant bypasses TMPRSS2-mediated fusion, exhibiting a distinct preference for the endosomal entry route, which shifts its tropism toward the upper respiratory tract rather than deep lung parenchyma.

Immune Response And Endothelial Dysfunction

Severe disease progression is driven by a dysregulated host immune response termed a cytokine storm.
This hyperinflammatory state involves the massive release of proinflammatory cytokines, including Interleukin-6, Tumor Necrosis Factor-alpha, and Interferon-gamma.
Direct viral infection of endothelial cells combines with cytokine-mediated injury to induce profound endothelial dysfunction and endotheliitis.
Damaged endothelium releases tissue factor and von Willebrand factor, triggering immunothrombosis.
Neutrophil extracellular traps propagate this process, culminating in microvascular thrombosis clinically evidenced by significantly elevated D-dimer and fibrinogen levels.

Pediatric Protection Mechanisms

Children typically experience milder acute disease due to physiological factors limiting viral replication and spread.
Pediatric respiratory tracts feature lower basal expression of Angiotensin-Converting Enzyme 2 receptors, restricting the initial viral load.
Children mount a highly robust innate immune response featuring elevated early interferon production, clearing the virus before the adaptive immune system can trigger a destructive cytokine storm.
Frequent exposure to endemic seasonal coronaviruses provides substantial cross-immunity.

Clinical Classifications And Acute Management

Disease Category	Clinical Defining Features	Standard Management Protocol
Asymptomatic	Positive molecular test completely lacking clinical symptoms.	Home isolation and strict monitoring; no specific pharmacological therapy required.
Mild Illness	Upper respiratory symptoms, fever, fatigue, vomiting, or diarrhea without hypoxia (SpO2 $\geq$ 94% on room air).	Home isolation and supportive care. Paracetamol administered at 10-15 mg/kg/dose. Corticosteroids and anticoagulants strictly contraindicated.
Moderate Illness	Presence of clinical pneumonia accompanied by rapid respiration for age or SpO2 between 90-93% on room air.	Hospital admission. Oxygen therapy to maintain SpO2 >94%. Dexamethasone or Methylprednisolone administered only in rapidly progressive cases.
Severe Illness	Severe pneumonia, Acute Respiratory Distress Syndrome, Septic Shock, or SpO2 <90% on room air.	Immediate intensive care admission. Requires non-invasive or invasive mechanical ventilation. Intravenous Corticosteroids strongly recommended. Remdesivir strictly not recommended for children under 18 years.

Multisystem Inflammatory Syndromes

Multisystem Inflammatory Syndrome In Children (MIS-C)

Represents a severe, life-threatening hyperinflammatory condition emerging 2 to 6 weeks following acute viral infection.
Pathogenesis relies on adaptive immune dysregulation where the viral spike protein acts as a superantigen, bypassing normal antigen processing to trigger massive T-cell activation and cytokine release.
Autoantibodies targeting host endothelial cells, gastrointestinal tissue, and immune cells drive widespread tissue damage.

Clinical Feature	Kawasaki Disease	Multisystem Inflammatory Syndrome In Children
Demographics	Infants and young children under 5 years; highest incidence in East Asian descent.	Older children and adolescents aged 6 to 12 years; higher incidence in African and Hispanic descent.
Fever Pattern	Unremitting fever persisting strictly > 5 days.	Fever > 38.0°C persisting for $\geq$ 24 hours, commonly lasting 3 to 5 days.
Shock And Hemodynamics	Shock is exceedingly rare (< 5% of cases).	Shock is a defining feature (50-80% of cases), requiring fluid and vasopressor support.
Gastrointestinal	Symptoms remain mild and secondary.	Severe abdominal pain, vomiting, or diarrhea present in 80-90% of cases, frequently mimicking appendicitis.
Cardiac Pathology	Primary complication involves coronary artery vasculitis and destructive aneurysms; ventricular function remains preserved.	Primary complication involves acute myocarditis triggering severe left ventricular dysfunction; coronary dilation remains mild and transient.
Hematology	Classic thrombocytosis and normal lymphocyte counts.	Profound thrombocytopenia (<150,000/μL) and severe absolute lymphopenia.
Biomarkers	Mild D-dimer and Ferritin elevations.	Massive Ferritin elevation resembling Macrophage Activation Syndrome; markedly elevated D-dimer indicating active coagulopathy.

Multisystem Inflammatory Syndrome In Neonates (MIS-N)

A distinct hyper-inflammatory state occurring in neonates born to mothers with a documented history of infection during pregnancy.
Pathogenesis involves the transplacental transfer of maternal IgG antibodies or inflammatory cytokines, which directly trigger immune activation and tissue damage within the neonate.
Clinical presentation is dominated by severe cardiovascular dysfunction, hypotension, arrhythmias, and persistent pulmonary hypertension.
Fever is notably absent in approximately 80% of documented MIS-N cases.

Management Protocols

Pharmacological Therapeutics

Pharmacological Agent	Dosage Guidelines	Clinical Indication
Paracetamol	10 to 15 mg/kg/dose every 4 to 6 hours.	Mild to severe acute disease for fever control.
Dexamethasone	0.15 mg/kg/dose twice daily (Maximum 6 mg).	Severe or critical acute disease.
Methylprednisolone	1 to 2 mg/kg/day.	First-line therapy for MIS-C and moderate acute disease.
Pulse Corticosteroids	10 to 30 mg/kg/day for 3 days.	Refractory MIS-C unresponsive to initial therapy.
Intravenous Immunoglobulin	2 g/kg infused over 12 to 24 hours.	First-line therapy for MIS-C and severe MIS-N.
Aspirin	3 to 5 mg/kg/day.	Antiplatelet therapy strictly indicated for all MIS-C patients.
Enoxaparin	1 mg/kg/dose twice daily.	Indicated for MIS-C patients featuring high thrombosis risk, massive D-dimer elevation, or severe ventricular dysfunction.

Management Of Refractory MIS-C

Patients demonstrating persistent fever or symptoms 48 to 72 hours following initial Immunoglobulin and Corticosteroid administration mandate escalation therapy.
Pulse Methylprednisolone serves as the immediate next step.
Biological targeted therapies are utilized for steroid-refractory states, featuring Anakinra (Interleukin-1 receptor antagonist) as the definitive first-choice biologic agent administered at 2 to 10 mg/kg/day.
Tocilizumab (Interleukin-6 inhibitor) and Infliximab (Tumor Necrosis Factor-alpha inhibitor) represent alternative biological options based on specific patient phenotypes.

Neonatal Considerations

Delivery room personnel must strictly don full Personal Protective Equipment, including N95 respirators, face shields, and gowns.
Delayed cord clamping for at least 60 seconds remains strongly recommended for vigorous neonates, carrying no increased risk of viral transmission.
Global guidelines strongly advocate for immediate rooming-in rather than routine maternal-neonatal separation.
Exclusive breastfeeding remains universally recommended; mothers must practice rigorous respiratory hygiene using triple-layer masks and strict hand washing prior to all neonatal contact.
Routine separation is actively discouraged unless the mother is critically ill.
The definitive neonatal diagnostic strategy mandates a viral nucleic acid amplification test at 24 hours of life to differentiate vertical from horizontal transmission.